uniQure (QURE) Stock Forecast & Price Target

uniQure NV experienced a significant revenue increase of 71% year-over-year, reaching $27.1 million in 2024, largely driven by $10 million from license revenue related to HEMGENIX royalties and $11 million from collaboration efforts. The company's probability of success (POS) for its gene therapy candidate, AMT-130, was raised to 75%, with expectations for a commercial launch by 2026, bolstered by positive FDA feedback and improved study enrollment. Additionally, risk-adjusted revenue projections have increased to $1.8 billion, indicating heightened confidence in AMT-130 as a potentially groundbreaking disease-modifying treatment for Huntington's disease.

The financial outlook for uniQure NV reflects significant challenges, including reduced revenue estimates resulting in anticipated annual peak revenues of just over $2 billion. A decline in research and development expenses, driven by a 65% workforce reduction and other cost-saving measures, raises concerns about the company's ability to advance its clinical pipeline effectively. Additionally, key risks such as commercial launch delays, regulatory uncertainties, and competition in the gene therapy market contribute to an overall speculative risk assessment that underscores potential volatility in both revenues and stock performance.